Vinblastine News and Research

RSS

Vinblastine is the active ingredient in a drug used together with other drugs to treat several types of cancer, including advanced Hodgkin lymphoma and advanced testicular germinal-cell cancers. It is also being studied in the treatment of other types of cancer. Vinblastine comes from the periwinkle plant Vinca rosea Linn. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of vinca alkaloid and a type of antimitotic agent.

Increasing anti-tumor activity of compound extracted from an Amazon plant

Researchers in Brazil have prepared modified forms of the alkaloids produced by Uncaria guianensis, a woody vine native to the Amazon Rainforest.

31 Oct 2019

Patients with advanced Hodgkin's lymphoma may benefit from radiotherapy after chemotherapy

Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy after chemotherapy even when all traces of the cancer appear to have gone, according to late breaking results presented at the ESTRO 38 conference today.

29 Apr 2019

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine chemotherapy, which is the standard of care.

5 Sep 2018

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder.

31 Aug 2018

OSU scientists find way to fight solid tumors using new cancer-drug delivery system

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment.

4 Apr 2017

Chemotherapy drug combination appears to increase production of eggs in women's ovaries

Women treated with a common chemotherapy drug combination have more young eggs in their ovaries afterwards, research has found.

6 Dec 2016

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.

9 Apr 2015

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.

16 Dec 2014

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

13 Oct 2014

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.

30 Jun 2014

Genetic changes can predict which patient will benefit from chemotherapy before bladder cancer surgery

Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.

31 May 2014

TSRI scientists find new way to boost effectiveness of anticancer drugs

Scientists at The Scripps Research Institute (TSRI) have found a way to make dramatic improvements to the cancer cell-killing power of vinblastine, one of the most successful chemotherapy drugs of the past few decades.

17 Sep 2013

Iridoid synthase can make powerful chemicals from catnip to vinblastine

Scientists have discovered an enzyme used in nature to make powerful chemicals from catnip to a cancer drug, vinblastine. The discovery opens up the prospect of producing these chemicals cheaply and efficiently.

22 Nov 2012

Radiotherapy redundant in low-risk Hodgkin lymphoma treatment

Children with low-risk Hodgkin lymphoma who respond well to chemotherapy may not require additional radiotherapy, suggest study results.

10 Jul 2012

Pediatric Hodgkin lymphoma can be treated without radiation and intensive chemotherapy

A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, infertility, heart and other problems later.

28 Jun 2012

Patients with muscle-invasive bladder cancer benefit from accelerated MVAC

For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery. A large randomized clinical trial published in 2003 demonstrated a survival benefit for neoadjuvant, or pre-surgical, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) using a standard dose and schedule.

18 May 2012

Salk scientists' discovery explains how a class of chemotherapy drugs works

The well-being of living cells requires specialized squads of proteins that maintain order. Degraders chew up worn-out proteins, recyclers wrap up damaged organelles, and-most importantly-DNA repair crews restitch anything that resembles a broken chromosome. If repair is impossible, the crew foreman calls in executioners to annihilate a cell. As unsavory as this last bunch sounds, failure to summon them is one aspect of what makes a cancer cell a cancer cell.

12 Mar 2012

MPC project to study how plant genes contribute to producing medicinal compounds

Scientists are about to make publicly available all the data they have so far on the genetic blueprint of medicinal plants and what beneficial properties are encoded by the genes identified.

15 Dec 2011